Table 1.
Background characteristics, severity and mortality of TB patients hospitalised before and during COVID-19 period
| Patients’ clinical profile | Number of new hospitalised TB patients | |||
|---|---|---|---|---|
| Overall period | Before and during COVID-19 period | |||
| Jan 2017- Sep 2022 (N = 168,332) | Before COVID-19 (Jan 2017- Feb 2020) (N = 99,936) | During COVID-19 (Mar 2020- Sep 2022) (N = 68,396) | p-value | |
| Gender | < 0.001 | |||
| Female | 49,772 (29.6) | 29,952 (30.0) | 19,820 (29.0) | |
| Male | 118,560 (70.4) | 69,984 (70.0) | 48,576 (71.0) | |
| Age group (years) | < 0.001 | |||
| < 15 | 2406 (1.4) | 1464 (1.5) | 942 (1.4) | |
| 15—59 | 85,522 (50.8) | 51,242 (51.3) | 34,280 (50.1) | |
| ≥ 60 | 80,404 (47.8) | 47,230 (47.3) | 33,174 (48.5) | |
| ICD-10 TB diagnosis | < 0.001 | |||
|
Pulmonary TB (Bacteriologically confirmed) |
72,359 (43.0) | 43,369 (43.4) | 28,990 (42.4) | |
| Pulmonary TB (Clinically diagnosed) | 69,618 (41.4) | 41,199 (41.2) | 28,419 (41.6) | |
| TB of nervous system | 5481 (3.3) | 3203 (3.2) | 2278 (3.3) | |
| TB of other organs | 14,435 (8.6) | 8731 (8.7) | 5704 (8.3) | |
| Miliary TB | 6439 (3.8) | 3434 (3.4) | 3005 (4.4) | |
| Charlson Comorbidity Index (CCI)* | < 0.001 | |||
| Mean (SD) | 0.64 (1.2) | 0.61 (1.2) | 0.67 (1.2) | |
| 0 | 110,438 (65.6) | 66,798 (66.8) | 43,640 (63.8) | |
| 1 | 35,310 (21.0) | 20,258 (20.3) | 15,052 (22.0) | |
| 2 | 11,139 (6.6) | 6333 (6.3) | 4806 (7.0) | |
| ≥ 3 to 29 | 11,445 (6.8) | 6547 (6.6) | 4898 (7.2) | |
| Mortality | 11,501 (6.8) | 6145 (6.1) | 5356 (7.8) | < 0.001 |
*Charlson comorbidity index (CCI) score ranged from 0–29. The higher score predicts increased mortality by weighing different comorbid conditions to measure the severity of patient[19]; TB, Tuberculosis